September 10, 2025International Journal of Molecular SciencesOpen Access

Immune Checkpoint Inhibition in Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Emerging Mechanisms and Personalized Clinical Strategies

View Full Paper

Ask AI

Bookmark

Authors

NNNicola Joseph NasserMount Sinai Hospital KSKunal K. SindhuMount Sinai Hospital LNLoor Nasser

Discussion

Member takes

Implication

This review examines immune checkpoint inhibitors' effects and challenges in brain metastases from non-small-cell lung cancer, indicating new personalized strategies.

Key Points

Immune checkpoint inhibitors improve outcomes in patients with brain metastases, targeting distinct mechanisms in non-small-cell lung cancer.
Evidence from clinical trials highlights varied efficacy of immune checkpoint inhibitors based on tumor microenvironment and patient characteristics.
The review emphasizes transcriptional changes in brain-tropic tumor cells and immune cell movement across the blood-brain barrier as vital factors.
Emerging strategies including surgical resection and biomarker evaluation are crucial for enhancing treatment personalization in affected patients.

Cite This Study

Nasser et al. (2025) studied this question.

synapsesocial.com/papers/68c23c66b210217d64789941 https://doi.org/10.3390/ijms26178624

View Full Paper

Ask AI

Bookmark

Implication

This review examines immune checkpoint inhibitors' effects and challenges in brain metastases from non-small-cell lung cancer, indicating new personalized strategies.

Immune Checkpoint Inhibition in Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Emerging Mechanisms and Personalized Clinical Strategies

Discussion

Member takes

Implication

Key Points

Cite This Study

Immune Checkpoint Inhibition in Patients with Brain Metastases from Non-Small-Cell Lung Cancer: Emerging Mechanisms and Personalized Clinical Strategies

Discussion

Member takes

Implication

Key Points

Cite This Study

Also Consider

Also Consider